The X-TOLE2 clinical trial now underway to examine XEN1101 administered as an adjunctive treatment for adult patients with focal onset seizuresDownload Brochure
French et al. "XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2B Study (X-TOLE) in Adults With Focal Epilepsy"
French et al. (Encore) "Phase 2b Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Onset Seizures (X-TOLE)"
Kenney et al. "Rapid Onset of Efficacy of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: Results From a Phase 2b Study (X-TOLE)"
Leung et al. "The Impact of Disease Severity on Efficacy From a Phase 2b Study of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)"
"Design of X-TOLE2 and X-TOLE3: Two Parallel, Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies to Evaluate the Safety and Efficacy of XEN1101 as Adjunctive Therapy in the Treatment of Focal Onset Epilepsy"
We hope you can visit our scientific exhibit taking place on Sunday, Dec. 4th from 2-5 pm in Room 207 C on Level 2 of the Music City Center. Or, stop by Xenon's booth #1028 to learn more about our novel product pipeline.
Let us know if you would like to learn more about Xenon's XEN1101 Phase 3 program, including our X-TOLE2, X-TOLE3, and X-ACKT clinical trials, by emailing us at email@example.com.